An open-label, single-dose, non-randomized, balanced design three-way cross-over study to examine the variability in absorption of GSK561679 using gamma scintigraphy, PillCam SB capsule and the acoustic vest in healthy males volunteers
Phase of Trial: Phase I
Latest Information Update: 07 Oct 2009
At a glance
- Drugs Verucerfont; Verucerfont
- Indications Depressive disorders; Irritable bowel syndrome; Social phobia
- Focus Pharmacokinetics
- Sponsors GlaxoSmithKline
- 24 Apr 2008 Status changed from initiated to completed according to ClinicalTrials.gov.
- 16 Oct 2007 New trial record.